Safety and tolerability of andecaliximab as monotherapy and in combination with an anti-PD-1 antibody in Japanese patients with gastric or gastroesophageal junction adenocarcinoma: a phase 1b study

BACKGROUND: Matrix metalloproteinase 9 (MMP9) is implicated in protumorigenic processes. Targeting either stromal or epithelial MMP9 reduces the incidence of metastasis. Andecaliximab is a monoclonal antibody that targets MMP9 with high affinity and selectivity. However, no study has examined whethe...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshikawa, Akie Kimura, Yamaguchi, Kensei, Muro, Kei, Takashima, Atsuo, Ichimura, Takashi, Sakai, Daisuke, Kadowaki, Shigenori, Chin, Keisho, Kudo, Toshihiro, Mitani, Seiichiro, Kitano, Shigehisa, Thai, Dung, Zavodovskaya, Marianna, Liu, JieJane, Boku, Narikazu, Satoh, Taroh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8739432/
https://www.ncbi.nlm.nih.gov/pubmed/34992093
http://dx.doi.org/10.1136/jitc-2021-003518

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8739432/
https://www.ncbi.nlm.nih.gov/pubmed/34992093
http://dx.doi.org/10.1136/jitc-2021-003518

Ejemplares similares